Radical prostatectomy is surgery to remove all of the prostate gland and some of the tissue around it, to treat prostate cancer.
Clinical factors including the time to biochemical recurrence following surgery can help predict the risk of prostate cancer death for patients following a radical prostatectomy, according to a study in the July 27 issue of JAMA: The Journal of the American Medical Association.
Men who have a higher rate of increase in their PSA value in the year prior to their prostate cancer diagnosis have a significantly higher risk of death following radiation therapy, according to a study in the July 27 issue of JAMA: The Journal of the American Medical Association.
Researchers at Johns Hopkins and The Brady Urological Institute have identified three risk factors and developed a simple reference tool that doctors can use to determine who is at high risk of death after prostate cancer recurrence following surgery.
A new study indicates there is no specific PSA value that has both high sensitivity and high specificity for monitoring healthy men for prostate cancer, but rather there is a continuum of prostate cancer risk at all values of PSA, according to a study in the July 6 issue of JAMA: The Journal of the American Medical Association.
Researchers led by Dr. Shiv Srivastava from the Center for Prostate Disease Research (CPDR), Uniformed Services University of the Health Sciences (USU), report the groundbreaking discovery of the ETS-Related Gene (ERG) as one of the frequent proto-oncogene overexpressions in prostate cancer cells.
The obesity study examined the association between body mass index - weight to height ratio - and prostate cancer in 787 men undergoing biopsy due to an elevated tumor marker in the blood or an abnormal physical exam at a Veterans Affairs hospital in California between 1998 and 2002.
A study by Swedish researchers has found that men who opt to have cancerous prostates surgically removed, have higher long-term survival rates than those who delay the operation, and the benefits of surgery may be greatest for men under 65.
Gen-Probe's prototype urine test for PCA3 gene expression may help improve the diagnosis of prostate cancer, according to three early-stage studies presented as posters at the American Association for Clinical Chemistry's 37th Annual Oak Ridge Conference and the Annual Meeting of the American Association for Cancer Research (AACR).
New findings from Mayo Clinic indicate that cT3 prostate cancer, a disease in which the cancer has spread locally from inside the prostate to immediately outside it, is operable and has 15-year cancer survival rates of almost 80 percent.
Marital status, high school education, and race/ethnicity may play a far greater role in patients' treatment decisions than previously believed.
Endocare today announced that 10-year follow-up data from a retrospective study demonstrated that cryoablation as a treatment for prostate cancer has a biochemical disease free survival rate of 77 percent.
Treatment for prostate cancer leads to significant five-year declines in sexual and urinary function, according to a new study. However, general and other specific health-related quality of life factors, such as bowel function, are not affected.
After spending more than seven months in the hospital following his premature birth, the parents of Dakota Templeton were hopeful that his worst medical challenges were behind him. Unfortunately, those hopes were not realized.
Surgical teams are now performing robotic surgery for prostate cancer with enhanced efficiency, comfort and communication using this unique technology.
After prostate cancer surgery, obese men are more likely than men with normal weight to have high levels of prostate specific antigen (PSA), a marker for cancer recurrence, according to a study led by Johns Hopkins researchers.
When a man is diagnosed with early-stage prostate cancer, he must decide among four different treatment methods, each of which carries its own set of benefits and risks.
Radiation oncologists and urologists at The Cleveland Clinic have performed their 1,000th prostate brachytherapy, a type of treatment in which radioactive seeds are implanted in the prostate to destroy cancerous cells.
Earlier this year, the University of Kentucky Hospital was the first hospital in Kentucky to perform a minimally invasive, coronary artery bypass graft using surgical robotic instruments.
Men who have their prostates removed may benefit from radiation therapy if their cancer returns, according to a new study. Experts say about 30,000 men in the United States who undergo surgery to have their prostates removed will have their cancer return.